eligibility_summary
Eligibility: R/R B‑cell lymphoma (FL G1‑3B, MZL, WM, MCL, tNHL, DLBCL, high‑grade BCL, PMBCL, RT in expansion) after ≥1 anti‑CD20 regimen, with FDG‑avid or measurable disease, contraception required if of childbearing potential. Exclude: pregnancy/breastfeeding, ECOG ≥2, weight <50 kg, organ dysfunction, recent therapy/radiation, immunosuppression, recent allo HSCT/CAR‑T or organ transplant, non‑malignant CNS disorders, major CV disease/infection, recent live vaccine, albumin/DMSO allergy, unsafe conditions.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: NCT05950334 (Phase 1). Interventions and mechanisms: - FT522: investigational, off-the-shelf allogeneic iPSC-derived natural killer (NK) cell therapy, intended to kill tumor cells directly and augment antibody-dependent cellular cytotoxicity (ADCC) when paired with anti-CD20 antibodies. - Rituximab: chimeric IgG1 monoclonal antibody targeting CD20 on B cells, mediates ADCC, complement-dependent cytotoxicity (CDC), and apoptosis. - Conditioning (Regimen A only): Cyclophosphamide and Bendamustine (alkylating agents causing DNA crosslinks) and/or Fludarabine (purine analog inhibiting DNA synthesis), used for lymphodepletion and cytotoxic tumor reduction. Targets/cellular pathways: - Malignant B cells expressing CD20 (and typically CD19). - NK cell FcγRIIIa (CD16)-mediated ADCC pathway engaged by rituximab opsonization. - Complement activation via rituximab. - DNA damage/lymphodepletion pathways via cyclophosphamide, bendamustine, and fludarabine.